Conference Coverage
Latest News
Latest NCCN Melanoma Guidelines Capture Dynamic of Constantly Evolving Best Practice
Many of the changes in the 2024 NCCN guidelines capture incremental advances rather than a radical departure from previous practice.
Conference Coverage
B-ALL: CAR-T Outperforms Novel Therapies
Real-world patients with B-ALL who relapsed post transplant showed significantly better outcomes with CAR T-cell therapy versus novel alternative...
Conference Coverage
MM:New Tool Gauges Post–CAR T Relapse Risk
Key disease, treatment, and inflammation risk factors predict patients at a higher risk of relapse.
Latest News
Expert Hopes to Expand Ohio Model of Melanoma Case Reporting
“This is an opportunity to improve state health, quality improvement projects, help providers, and gain recognition as a center of excellence,” Dr...
Conference Coverage
Regrowth Predicts Metastasis in Rectal Cancer Watch and Wait
Investigators compared outcomes for ‘watch-and-wait’ patients with those who had total mesorectal excisions after neoadjuvant therapy.
Latest News
While Rare, Periocular Melanoma May Be Slightly Increasing
Most cases involve the intraocular part of the eye and the uvea.
Latest News
More Than 100K New Cutaneous Melanoma Diagnoses Expected in 2024
Individuals can track their UV exposure with a variety of wearable devices and apps.
Conference Coverage
Small PFS gain in metastatic prostate cancer with TKI and ICI
Expert questions the choice of an androgen receptor pathway inhibitor (ARPI) switch as the control arm of the study.
Conference Coverage
Combo Tx Best in Metastatic Prostate Cancer with HRR Mutations
PFS was better with abiraterone/prednisone and olaparib vs. monotherapy in men with metastatic castration-resistant prostate cancer with DNA...
Conference Coverage
Stockholm3 Prostate Test Bests PSA for Prostate Cancer Risk in North America
The Stockholm3 blood test, using a multiplex algorithm, shows benefits over PSA in a diverse, multi-ethnic cohort beyond a Swedish population...
Conference Coverage
ctDNA Clearance Improves Prediction of Relapse Risk in Urothelial Cancer
The combination of ctDNA with other biomarkers shows further benefits in predicting treatment response.